Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
Open Access
- 2 April 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (4) , e1927
Abstract
Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNß in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNß therapy. Large scale gene expression profiling was performed on peripheral blood of 16 RRMS patients at baseline and one month after the start of IFNß therapy. Differential gene expression was analyzed by Significance Analysis of Microarrays. Subsequent expression analyses on specific genes were performed after three and six months of treatment. Peripheral blood mononuclear cells (PBMC) were isolated and stimulated in vitro with IFNß. Genes of interest were measured and validated by quantitative realtime PCR. An independent group of 30 RRMS patients was used for validation. Pharmacogenomics revealed a marked variation in the pharmacological response to IFNß between patients. A total of 126 genes were upregulated in a subset of patients whereas in other patients these genes were downregulated or unchanged after one month of IFNß therapy. Most interestingly, we observed that the extent of the pharmacological response correlates negatively with the baseline expression of a specific set of 15 IFN response genes (R = −0.7208; p = 0.0016). The negative correlation was maintained after three (R = −0.7363; p = 0.0027) and six (R = −0.8154; p = 0.0004) months of treatment, as determined by gene expression levels of the most significant correlating gene. Similar results were obtained in an independent group of patients (n = 30; R = −0.4719; p = 0.0085). Moreover, the ex vivo results could be confirmed by in vitro stimulation of purified PBMCs at baseline with IFNß indicating that differential responsiveness to IFNß is an intrinsic feature of peripheral blood cells at baseline. These data imply that the expression levels of IFN response genes in the peripheral blood of MS patients prior to treatment could serve a role as biomarker for the differential clinical response to IFNß.Keywords
This publication has 37 references indexed in Scilit:
- A subtype of multiple sclerosis defined by an activated immune defense programGenes & Immunity, 2006
- Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyAnnals of Neurology, 2006
- Lupus‐like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9pArthritis & Rheumatism, 2006
- Transcription-Based Prediction of Response to IFNβ Using Supervised Computational MethodsPLOS Biology, 2004
- The Interferon-Inducible Stat2:Stat1 Heterodimer Preferentially Binds In Vitro to a Consensus Element Found in the Promoters of a Subset of Interferon-Stimulated GenesJournal of Interferon & Cytokine Research, 2001
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male VolunteersJournal of Interferon & Cytokine Research, 1996
- Application of Genomic DNA Affinity Chromatography Identifies Multiple Interferon-α-regulated Stat2 ComplexesJournal of Biological Chemistry, 1996
- Formation of STAT1-STAT2 Heterodimers and Their Role in the Activation of IRF-1 Gene Transcription by Interferon-αJournal of Biological Chemistry, 1996
- CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSISThe Lancet, 1985